Wednesday, July 8, 2026

Patent intelligence · US

US 11191737

Enhanced delivery epinephrine compositions

granted A61KA61K31/085A61K31/137A61K36/61
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 17
Related coverage 1
Patent details — US 11191737

Quick answer

US 11191737 (Enhanced delivery epinephrine compositions) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
28
CPC classes
A61K, A61K31/085, A61K31/137, A61K36/61, A61K47/10, A61K47/12

More from Aquestive Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12427121

    Enhanced delivery epinephrine compositions

    Aquestive Therapeutics, Inc. · Expires Sep 25, 2045

    granted
  2. US 12403090

    Oral film compositions and dosage forms having precise active dissolution profiles

    Aquestive Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  3. US 12290597

    Oral film compositions and dosage forms having precise active dissolution profiles

    Aquestive Therapeutics, Inc. · Expires May 1, 2045

    granted
  4. US 12023309

    Enhanced delivery epinephrine compositions

    Aquestive Therapeutics, Inc. · Expires Jun 27, 2044

    granted
  5. US 11541002

    Oral film compositions and dosage forms having precise active dissolution profiles

    Aquestive Therapeutics, Inc. · Expires Dec 29, 2042

    granted
  6. US 11273131

    Pharmaceutical compositions with enhanced permeation

    Aquestive Therapeutics, Inc. · Expires Mar 10, 2042

    granted
  7. US 11129799

    Dual lane coating

    Aquestive Therapeutics, Inc. · Expires Sep 23, 2041

    granted

Related coverage

Frequently asked questions

What is US patent 11191737?

US 11191737 (Enhanced delivery epinephrine compositions) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11191737?

Aquestive Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.

When does US 11191737 expire?

Our index shows an expiration date of Dec 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.